GSK said the Food and Drug Administration approved Blujepa as an oral treatment for uncomplicated urogenital gonorrhea.

The British pharmaceutical group on Thursday said the agency gave the green light for a supplemental new-drug application of Blujepa for adults and children 12 and older with limited or no alternative options for the treatment of gonorrhea.

Gonorrhea is a sexually transmitted infection caused by Neisseria gonorrhoeae that affects both men and women and can lead to infertility and other sexual and reproductive-health complications. GSK said there is currently no licensed vaccine in the U.S. for the prevention of gonorrhea infections, with standard treatment relying on an injectable antibiotic.

GSK said the FDA's approval means Blujepa is now available to patients in the U.S. as an alternative, when appropriate.

https://www.marketscreener.com/news/gsk-says-fda-approved-oral-treatment-for-gonorrhea-ce7d50dbdd88fe23